These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

595 related items for PubMed ID: 15834435

  • 1. Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma.
    Arora M, McGlave PB, Burns LJ, Miller JS, Barke JN, Defor TE, Weisdorf DJ.
    Bone Marrow Transplant; 2005 Jun; 35(12):1133-40. PubMed ID: 15834435
    [Abstract] [Full Text] [Related]

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 3. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma.
    Reynolds C, Ratanatharathorn V, Adams P, Braun T, Silver S, Ayash L, Carson E, Eisbruch A, Dawson LA, McDonagh K, Ferrara J, Uberti J.
    Bone Marrow Transplant; 2001 Apr; 27(8):801-7. PubMed ID: 11477436
    [Abstract] [Full Text] [Related]

  • 4. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma.
    Shimoni A, Smith TL, Aleman A, Weber D, Dimopoulos M, Anderlini P, Andersson B, Claxton D, Ueno NT, Khouri I, Donato M, Korbling M, Alexanian R, Champlin R, Giralt S.
    Bone Marrow Transplant; 2001 Apr; 27(8):821-8. PubMed ID: 11477439
    [Abstract] [Full Text] [Related]

  • 5. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED, Cioc A, Defor T, Dolan M, Weisdorf D.
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [Abstract] [Full Text] [Related]

  • 6. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
    Kröger N, Perez-Simon JA, Myint H, Klingemann H, Shimoni A, Nagler A, Martino R, Alegre A, Tomas JF, Schwerdtfeger R, Kiehl M, Fauser A, Sayer HG, Leon A, Beyer J, Zabelina T, Ayuk F, San Miguel JF, Brand R, Zander AR.
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):698-708. PubMed ID: 15389436
    [Abstract] [Full Text] [Related]

  • 7. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J, Shepherd JD, Sutherland HJ, Nevill TJ, Nitta J, Le A, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Toze CL, Smith CA, Barnett MJ, Song KW.
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [Abstract] [Full Text] [Related]

  • 8. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
    Zhang XH, Huang XJ, Liu KY, Xu LP, Liu DH, Chen H, Chen YH, Wang JZ, Han W, Lu DP.
    Chin Med J (Engl); 2007 Mar 20; 120(6):463-8. PubMed ID: 17439737
    [Abstract] [Full Text] [Related]

  • 9. Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning--evidence for a superior outcome using melphalan combined with total body irradiation.
    Hunter HM, Peggs K, Powles R, Rahemtulla A, Mahendra P, Cavenagh J, Littlewood T, Potter M, Hunter A, Pagliuca A, Williams CD, Cook G, Towlson K, Marks David I, Russell NH, Clinical Trials Committee of the British Society of Blood and Marrow Transplantation (BSBMT).
    Br J Haematol; 2005 Feb 20; 128(4):496-502. PubMed ID: 15686458
    [Abstract] [Full Text] [Related]

  • 10. Non-myeloablative conditioning and allogeneic transplantation for multiple myeloma.
    Osman K, Elliott B, Mandeli J, Scigliano E, Malone A, Isola L, Grosskreutz C.
    Am J Hematol; 2010 Apr 20; 85(4):249-54. PubMed ID: 20162541
    [Abstract] [Full Text] [Related]

  • 11. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect.
    Alyea E, Weller E, Schlossman R, Canning C, Mauch P, Ng A, Fisher D, Gribben J, Freeman A, Parikh B, Richardson P, Soiffer R, Ritz J, Anderson KC.
    Bone Marrow Transplant; 2003 Dec 20; 32(12):1145-51. PubMed ID: 14647268
    [Abstract] [Full Text] [Related]

  • 12. Beta-2-microglobulin level predicts outcome following autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
    Stella-Holowiecka B, Czerw T, Holowiecka-Goral A, Giebel S, Wojnar J, Holowiecki J.
    Transplant Proc; 2007 Nov 20; 39(9):2893-7. PubMed ID: 18022010
    [Abstract] [Full Text] [Related]

  • 13. Allogeneic myeloablative transplantation for patients aged 50 years and over.
    Yanada M, Emi N, Naoe T, Sakamaki H, Iseki T, Hirabayashi N, Karasuno T, Chiba S, Atsuta Y, Hamajima N, Takahashi S, Kato S.
    Bone Marrow Transplant; 2004 Jul 20; 34(1):29-35. PubMed ID: 15156161
    [Abstract] [Full Text] [Related]

  • 14. Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma.
    Bruno B, Sorasio R, Patriarca F, Montefusco V, Guidi S, Busca A, Scimé R, Console G, Milone G, Marotta G, Dominietto A, Giaccone L, Rotta M, Falda M, Bacigalupo A, Bosi A, Corradini P, Fanin R, Pollichieni S, Boccadoro M, Gruppo Italiano Trapianto Midollo Osseo.
    Eur J Haematol; 2007 Apr 20; 78(4):330-7. PubMed ID: 17331132
    [Abstract] [Full Text] [Related]

  • 15. Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease.
    Yanada M, Naoe T, Iida H, Sakamaki H, Sakura T, Kanamori H, Kodera Y, Okamoto S, Kanda Y, Sao H, Asai O, Nakai K, Maruta A, Kishi K, Furukawa T, Atsuta Y, Yamamoto K, Tanaka J, Takahashi S.
    Bone Marrow Transplant; 2005 Nov 20; 36(10):867-72. PubMed ID: 16113659
    [Abstract] [Full Text] [Related]

  • 16. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications.
    Majhail NS, Mothukuri JM, Brunstein CG, Weisdorf DJ.
    Biol Blood Marrow Transplant; 2009 May 20; 15(5):564-73. PubMed ID: 19361748
    [Abstract] [Full Text] [Related]

  • 17. Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation.
    Gorin NC, Labopin M, Frassoni F, Milpied N, Attal M, Blaise D, Meloni G, Iori AP, Michallet M, Willemze R, Deconninck E, Harousseau JL, Polge E, Rocha V.
    J Clin Oncol; 2008 Jul 01; 26(19):3183-8. PubMed ID: 18506024
    [Abstract] [Full Text] [Related]

  • 18. The allogeneic dilemma.
    Harousseau JL.
    Bone Marrow Transplant; 2007 Dec 01; 40(12):1123-8. PubMed ID: 17680016
    [Abstract] [Full Text] [Related]

  • 19. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
    Shigematsu A, Kondo T, Yamamoto S, Sugita J, Onozawa M, Kahata K, Endo T, Shiratori S, Ota S, Obara M, Wakasa K, Takahata M, Takeda Y, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M.
    Biol Blood Marrow Transplant; 2008 May 01; 14(5):568-75. PubMed ID: 18410899
    [Abstract] [Full Text] [Related]

  • 20. Comorbidity index does not predict outcome in allogeneic myeloablative transplants conditioned with fludarabine/i.v. busulfan (FluBu4).
    Patel P, Sweiss K, Nimmagadda S, Gao W, Rondelli D.
    Bone Marrow Transplant; 2011 Oct 01; 46(10):1326-30. PubMed ID: 21132027
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.